Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study

Conditions

• Malignant Digestive System Neoplasm
• Malignant Female Reproductive System Neoplasm
• Malignant Genitourinary System Neoplasm

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Accepted

Interventions

• Non-Interventional Study — OTHER
  Non-interventional study
• Non-Interventional Study — OTHER
  Non-interventional study
• Non-Interventional Study — OTHER
  Non-interventional study

Study Details

This study evaluates the use of extended venous thromboembolism prophylaxis (ePPx) following abdominopelvic cancer surgery within the NCI Community Oncology Research Program (NCORP) network, targeting surgeons and surgical advanced practice providers (APPs).

Key Dates

Start date

Jan 15, 2026

Status verified

Apr 2026

Primary completion

Dec 1, 2026

Completion

Jun 1, 2027

Study Design

Enrollment

500 participants (estimated)

Arms

• Arm: Observational Part 1
  Surgeons and APPs complete a survey on study. After completion of surgeon or APP survey, site contact person or CCDR lead complete site surveys on study.
• Arm: Observational Part 2
  Subset of surgeons and APPs from Part 1 complete a semi-structured interview on study.
• Arm: Observational Part 3
  Site contact person or CCDR lead complete a survey to identify a EHR Report Specialist on study. EHR Report Specialist performs an EHR Data Extraction and provides feedback on the process in a survey.

Primary Outcome Measure

Self-reported utilization of guideline concordant ePPx for surgeons (Part 1) [ Time Frame: After 1 year from start of Part 1 ]

Central Contacts

• Karen Craver
  336-716-0891
  [email protected]

Locations (58)

Find similar trials in Fort Smith, AR

Related Studies

• 2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
  PHASE2 · Recruiting · Emory University · Atlanta, Georgia
• Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
  PHASE1 · Recruiting · M.D. Anderson Cancer Center · Baltimore, Maryland
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
  PHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
• Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
  PHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama